Eric Sievers' departure as Chief Medical Officer of BioAtla, Inc. was reported; the filing names no successor. As of November 4, 2026, BioAtla, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 29, 2026, naming 1 departure (Form 8-K, September 29, 2026).
Sell to companies like BioAtla, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
BioAtla, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-29. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as BioAtla, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-03-02 (layoff filings and notices).
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-29 | Out | Chief Medical Officer | 8-K, 2026-09-29 |
Selling to them or working with them? See who runs BioAtla, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on BioAtla, Inc. and the records around it.
BioAtla, Inc. elsewhere on the record
- Layoff notices Mar 2026
- Who owns it
Watch BioAtla, Inc.
Get an email when BioAtla, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioAtla, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BioAtla, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioAtla, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads BioAtla, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Eric Sievers, departure reported (filed 2026-09-29). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on BioAtla, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at BioAtla, Inc., with the record behind each one.
Find candidates like Chief Medical Officer at BioAtla, Inc.Every change, in the filing's words
Departing: Eric Sievers, Chief Medical Officer
(b) Dr. Sievers' Resignation and Consulting Agreement On September 25, 2026, Dr. Eric Sievers resigned from his position as the Company's Chief Medical Officer to pursue interests outside of the Company.
- Dr. Sievers will continue as a consultant to the Company, subject to the terms of a consulting agreement dated September 25, 2026 (the "Consulting Agreement") entered into between the Company and Dr. Sievers.
- Pursuant to the terms of the Consulting Agreement, in exchange for performing a number of hours of consulting services reasonably requested by the Company through December 31, 2026, Dr. Sievers is eligible to receive a one-time payment of $159,000, contingent upon the Company's achievement of certain capital raising milestones by December 31, 2026.
- For the period after January 1, 2027 to June 30, 2027, Dr. Sievers shall be paid at an hourly rate proportional to his base salary as of his separation date.
- The term of the Consulting Agreement will expire on June 30, 2027, unless mutually extended by the parties.
- Neither Milestone #1 nor Milestone #2 was completed.
- In view of the ongoing strategic process, on September 24, 2026, the Board approved a partial reinstatement of the retention bonus program for Mr. Vasquez which provides for a cash payout contingent upon the achievement of Milestone #2 by December 31, 2026.
- Mr. Vasquez's target retention bonus amount for Milestone #2 is $148,888, representing 40% of Mr. Vasquez's annual base salary.
- The payout for Milestone #2 is subject to a sliding scale.
Tools for this story
Each opens in a new tab, filled in for BioAtla, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.